Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eye implant to dispense ganciclovir data

Results of a Phase II trial of the implant from CHIR's Chiron Vision Corp. unit (Irvine, Calif.) showed elimination of signs of active infection for a median of 226 days, about eight

Read the full 320 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE